6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Suppression of Hepatocellular Carcinoma Progression through FOXM1 and EMT Inhibition via Hydroxygenkwanin-Induced miR-320a Expression

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Daphne genkwa, a Chinese medicinal herb, is used frequently in Southeast Asian countries to treat diseases; the flavonoid hydroxygenkwanin (HGK) is extracted from its flower buds. The bioactivity of HGK, particularly as an anti-liver cancer agent, has not been explored. In this study, human hepatocellular carcinoma (HCC) cell lines and an animal xenograft model were employed to investigate both the activity of HGK against liver cancer and its cellular signaling mechanisms. HCC cells treated with HGK were subjected to cell function assays. Whole transcriptome sequencing was used to identify genes whose expression was influenced by HGK, and the flavonoid’s cancer suppression mechanisms were further investigated through gain- and loss-of-function assays. Finally, in vitro findings were tested in a mouse xenograft model. The data showed that HGK induced the expression of the microRNA miR-320a, which in turn inhibited the expression of the transcription factor ‘forkhead box protein M1’ (FOXM1) and downstream FOXM1-regulated proteins related to epithelial–mesenchymal transition, thereby leading to the suppression of liver cancer cell growth and invasion. Significant inhibition of tumor growth was also observed in HGK-treated mice. Hence, the present study demonstrated the activity of HGK against liver cancer and validated its potential use as a therapeutic agent.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          Hepatocellular carcinoma review: current treatment, and evidence-based medicine.

          Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide. Multiple treatment options are available for HCC including curative resection, liver transplantation, radiofrequency ablation, trans-arterial chemoembolization, radioembolization and systemic targeted agent like sorafenib. The treatment of HCC depends on the tumor stage, patient performance status and liver function reserve and requires a multidisciplinary approach. In the past few years with significant advances in surgical treatments and locoregional therapies, the short-term survival of HCC has improved but the recurrent disease remains a big problem. The pathogenesis of HCC is a multistep and complex process, wherein angiogenesis plays an important role. For patients with advanced disease, sorafenib is the only approved therapy, but novel systemic molecular targeted agents and their combinations are emerging. This article provides an overview of treatment of early and advanced stage HCC based on our extensive review of relevant literature.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide.

            High-quality data on liver cancers by probable cause are scarce in many regions of the world. The United Nations recently set a goal of eliminating viral hepatitis as a major public health threat by 2030. We aimed to estimate the number of new cases of cancers attributable to hepatitis B virus (HBV) and hepatitis C virus (HCV) at a global, regional and country level, and by development status. We used data on the prevalence of HBV and HCV in hepatocellular carcinoma from a systematic review including 119,000 cases in 260 studies covering 50 countries. A statistical model was constructed to extrapolate empirical data to countries without prevalence data. Country-specific numbers of liver cancer cases attributable to HBV and HCV were calculated using data from GLOBOCAN 2012. Globally, 770,000 cases of liver cancer occurred worldwide in 2012, of which 56% (95% CI: 52-60) were attributable to HBV and 20% (95% CI: 18-22) to HCV. Currently, HBV causes approximately two out of three cases of liver cancer in less developed countries but one in four cases in more developed countries and shows a much higher degree of geographical aggregation in Eastern Asia and sub-Saharan Africa than HCV. These estimates help set priorities for liver cancer prevention. High-coverage HBV vaccination will be transformational in HBV-endemic countries but the prevention of HCV transmission and the treatment of chronic carriers of both viruses requires new scalable solutions.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              FOXM1 in Cancer: Interactions and Vulnerabilities.

              FOXM1 is a transcription factor of the Forkhead family that is required for cell proliferation of normal cells. However, FOXM1 is repeatedly overexpressed in a variety of human cancers, and it has been implicated in all major hallmarks of cancer delineated by Hanahan and Weinberg. It has been postulated that the oncogenic potential of FOXM1 is determined by its capacity to transactivate target genes that are implicated in different phases of cancer development. However, FOXM1 may also play an oncogenic role by interacting with other proteins, such as β-catenin or SMAD3 to induce oncogenic WNT and TGFβ signaling pathways, respectively. In this review, I will discuss the protein-protein interactions of FOXM1 that are critical for cancer development and may represent novel targets for anticancer drugs. Cancer Res; 77(12); 3135-9. ©2017 AACR.
                Bookmark

                Author and article information

                Journal
                Biomolecules
                Biomolecules
                biomolecules
                Biomolecules
                MDPI
                2218-273X
                21 December 2019
                January 2020
                : 10
                : 1
                : 20
                Affiliations
                [1 ]Kidney Research Center, Chang Gung Memorial Hospital, Tao-Yuan 33305, Taiwan; d928209@ 123456gmail.com
                [2 ]Tissue Bank, Chang Gung Memorial Hospital, Tao-Yuan 33305, Taiwan; d49417002@ 123456gmail.com (C.-Y.C.); chinchuan@ 123456mail.cgu.edu.tw (C.-C.C.)
                [3 ]Graduate Institute of Health Industry Technology and Research Center for Industry of Human Ecology, College of Human Ecology, Chang Gung University of Science and Technology, Tao-Yuan 33303, Taiwan
                [4 ]Department of Pathology and Laboratory Medicine Taipei Veterans General Hospital, Hsinchu Branch, Hsin-chu 31064, Taiwan; dammy310@ 123456yahoo.com.tw
                [5 ]Department of Medical Laboratory Science and Biotechnology, Yuanpei University of Medical Technology, Hsin-chu 30015, Taiwan
                [6 ]Graduate Institute of Natural Products, Chang Gung University, Tao-Yuan 33303, Taiwan; ylleu@ 123456mail.cgu.edu.tw
                [7 ]Department of Pathology and Laboratory Medicine, Taoyuan Armed Forces General Hospital, Tao-Yuan 32551, Taiwan; junn9liang@ 123456yahoo.com.tw
                [8 ]Biomedical Engineering Department, Ming Chuan University, Tao-Yuan 33348, Taiwan
                [9 ]Chinese Herbal Medicine Research Team, Healthy Aging Research Center, Chang Gung University, Tao-Yuan 33303, Taiwan
                [10 ]Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Tao-Yuan 33305, Taiwan
                [11 ]Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Tao-Yuan 33305, Taiwan; lioumj@ 123456cgmh.org.tw
                [12 ]Liver Research Center, Department of Hepato-Gastroenterology, Chang Gung Memorial Hospital, Tao-Yuan 33305, Taiwan
                Author notes
                [* ]Correspondence: cellww@ 123456gmail.com ; Tel.: +886-3-3281200 (ext. 5412)
                [†]

                These authors contributed equally to the work.

                Author information
                https://orcid.org/0000-0002-3476-0513
                https://orcid.org/0000-0003-2878-1702
                https://orcid.org/0000-0002-1649-6798
                https://orcid.org/0000-0001-9248-9031
                Article
                biomolecules-10-00020
                10.3390/biom10010020
                7022487
                31877715
                8d7b20c4-9bb5-4b1e-94a6-fd532be367d9
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 22 October 2019
                : 18 December 2019
                Categories
                Article

                liver cancer,hydroxygenkwanin,epithelial–mesenchymal transition,foxm1,mir-320a

                Comments

                Comment on this article